Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample
Carmela Nardelli(Ceinge Biotecnologie Avanzate (Italy)), Lucio Pastore(Ceinge Biotecnologie Avanzate (Italy)), Lorella Tripodi(Ceinge Biotecnologie Avanzate (Italy)), Ciro Imbimbo(University of Naples Federico II), Savio Domenico Pandolfo(University of Salerno), Achille Aveta(University of Naples Federico II), Giuseppe Castaldo(Federico II University Hospital), Filippo Russo(CEINGE Biotecnologie Avanzate Franco Salvatore (Italy))
Cited by 45
Related Papers
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
|Biomedicines|2023|161
Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19
|Scientific Reports|2021|149
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study
|Journal of Clinical Medicine|2021|131
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma
|Journal of Clinical Medicine|2023|129